FDA Inspection Trends 2025: What Clinical Teams Need to Know
8 min read · 2025-01-15 · AuditingLab Team
Recent FDA inspection data reveals shifting focus areas for clinical sites. Learn how to prepare your team for the latest regulatory priorities.
FDA inspection focus has shifted toward data integrity, electronic records compliance, and remote inspection readiness. Clinical teams that proactively address these areas see significantly fewer critical findings. Key priorities include ensuring audit trails are complete and unaltered, training staff on FDA's Bioresearch Monitoring (BIMO) program expectations, and having mock inspection protocols in place before any scheduled visit.
Data Integrity: The Top FDA Finding Category
Data integrity consistently ranks as the leading source of critical and major findings in FDA BIMO inspections. Inspectors are trained to look for signs of backdating, altered entries, and audit trail gaps — issues that are far easier to detect in electronic systems than sponsors expect.
The FDA's expectation is ALCOA+: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available. Any entry that cannot be traced to a specific individual at a specific time is a potential integrity violation.
- Confirm your CTMS and EDC systems produce unalterable, time-stamped audit trails
- Conduct a pre-inspection audit trail review across all electronic source documents
- Train all site staff on what constitutes a data integrity event and how to report it
- Document correction procedures — cross out, date, initial, and explain; never use correction fluid
- Ensure system-generated audit trails cannot be disabled or modified by site users
Electronic Records Compliance Under 21 CFR Part 11
21 CFR Part 11 governs electronic records and signatures in FDA-regulated clinical trials. Inspectors now arrive with specific Part 11 checklists and frequently request demonstrations of system controls rather than accepting documentation alone.
Common gaps include electronic signatures that lack the required signer identity linking, audit trails that are not routinely reviewed by the QA function, and system validation documentation that is incomplete or outdated.
- Validate electronic systems used for source data capture before first patient use
- Maintain current IQ/OQ/PQ documentation for all clinical software systems
- Demonstrate that electronic signatures are linked to specific user credentials
- Show that audit trail reviews are part of routine QA activities, not one-time events
- Keep system access logs and user role change records for the full retention period
Remote Inspection Readiness
The FDA has normalized hybrid inspections — combining on-site presence with remote document review sessions. Sites that were prepared for document transmission requests during COVID-19 inspections have maintained that posture and consistently score better.
Remote readiness means more than having PDFs available. It means knowing exactly where every document lives, who can authorize its release, and how quickly your team can respond to an inspector's document request during a live inspection.
- Maintain an indexed Trial Master File (TMF) that can be shared electronically within hours
- Designate a document coordinator responsible for all inspector requests during an inspection
- Test your document retrieval process with a mock document request exercise
- Ensure remote access capabilities are tested and secure before an inspection begins
- Have protocol deviations, SAEs, and consent records organized and immediately accessible
BIMO Program Focus Areas in 2025
The FDA's Bioresearch Monitoring program has expanded its focus on sponsor oversight of CROs and clinical sites. Sponsors that delegate functions to CROs remain responsible for the quality of that work, and inspectors will review oversight agreements, visit reports, and issue logs to verify that delegation was documented and monitored.
- Review all active CRO contracts to confirm oversight obligations are clearly defined
- Maintain evidence of sponsor oversight activities (visit reports, meeting minutes, issue logs)
- Ensure sponsor SOPs reference and govern CRO delegation procedures
- Conduct periodic audits of CRO performance, not just at study start and close-out
- Keep training records for all delegated personnel, including CRO staff performing sponsor functions
Key Takeaways
- Data integrity is the top FDA finding category — address audit trails and ALCOA+ compliance first
- Part 11 compliance must be demonstrated, not just documented
- Remote inspection readiness requires indexed TMFs and fast document retrieval capabilities
- Sponsor oversight of CROs is a growing inspection target in 2025
- Mock inspections remain the highest-ROI preparation activity for any scheduled FDA visit